{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:01:32Z","timestamp":1775728892489,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-025-03481-4","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T06:48:44Z","timestamp":1771224524000},"page":"1845-1853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Diffusing Lung Capacity for Carbon Monoxide on Mortality Risk in Patients with ASMD: Insights from a Post Hoc Analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Wim A.","family":"Wuyts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bonella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venediktos","family":"Kapetanakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pragya","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Gasparic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Pulikottil-Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"1\u20132","key":"3481_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","volume":"120","author":"EH Schuchman","year":"2017","unstructured":"Schuchman EH, Desnick RJ. Types A and B Niemann-Pick disease. Mol Genet Metab. 2017;120(1\u20132):27\u201333.","journal-title":"Mol Genet Metab"},{"key":"3481_CR2","volume-title":"The online metabolic and molecular bases of inherited disease","author":"EH Schuchman","year":"2019","unstructured":"Schuchman EH, Desnick RJ. Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, editors. The online metabolic and molecular bases of inherited disease. New York: McGraw-Hill Education; 2019."},{"issue":"1","key":"3481_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13023-017-0572-x","volume":"12","author":"MM McGovern","year":"2017","unstructured":"McGovern MM, Avetisyan R, Sanson BJ, Lidove O. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis. 2017;12(1):41.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3481_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beem.2014.08.004","volume":"29","author":"SDK Kingma","year":"2015","unstructured":"Kingma SDK, Bodamer OA, Wijburg FA. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract Res Clin Endocrinol Metab. 2015;29(2):145\u201357.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"3481_CR5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jpeds.2006.06.034","volume":"149","author":"MP Wasserstein","year":"2006","unstructured":"Wasserstein MP, Aron A, Brodie SE, Simonaro C, Desnick RJ, McGovern MM. Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. J Pediatr. 2006;149(4):554\u20139.","journal-title":"J Pediatr"},{"key":"3481_CR6","unstructured":"Wasserstein MP SE. Acid sphingomyelinase deficiency. In: Adam MP FJ, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]; 1993. Seattle: University of Washington; 2006 [Updated 2023 Apr 27]."},{"issue":"1","key":"3481_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13023-023-02686-6","volume":"18","author":"T Geberhiwot","year":"2023","unstructured":"Geberhiwot T, Wasserstein M, Wanninayake S, et al. Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B and A\/B). Orphanet J Rare Dis. 2023;18(1):85.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3481_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ymgme.2016.05.001","volume":"118","author":"D Cassiman","year":"2016","unstructured":"Cassiman D, Packman S, Bembi B, et al. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): literature review and report of new cases. Mol Genet Metab. 2016;118(3):206\u201313.","journal-title":"Mol Genet Metab"},{"key":"3481_CR9","first-page":"119","volume":"41","author":"GF Cox","year":"2018","unstructured":"Cox GF, Clarke LA, Giugliani R, McGovern MM. Burden of illness in acid sphingomyelinase deficiency: a retrospective chart review of 100 patients. JIMD Rep. 2018;41:119\u201329.","journal-title":"JIMD Rep"},{"issue":"1","key":"3481_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13023-024-03174-1","volume":"19","author":"E Mengel","year":"2024","unstructured":"Mengel E, Muschol N, Weinhold N, et al. A retrospective study of morbidity and mortality of chronic acid sphingomyelinase deficiency in Germany. Orphanet J Rare Dis. 2024;19(1):161.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3481_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ymgme.2012.06.015","volume":"107","author":"CE Hollak","year":"2012","unstructured":"Hollak CE, de Sonnaville ES, Cassiman D, et al. Acid sphingomyelinase (ASM) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients. Mol Genet Metab. 2012;107(3):526\u201333.","journal-title":"Mol Genet Metab"},{"key":"3481_CR12","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/PPA.S381371","volume":"17","author":"C Mansfield","year":"2023","unstructured":"Mansfield C, Nalysnyk L, Joshi D, Coulter J, Pulikottil-Jacob R. Impact of potential symptoms and risks associated with acid sphingomyelinase deficiency on patients and caregivers: a best-worst scaling study. Patient Prefer Adherence. 2023;17:927\u201339.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"3481_CR13","doi-asserted-by":"publisher","first-page":"20972","DOI":"10.1038\/s41598-021-99921-6","volume":"11","author":"R Pokrzywinski","year":"2021","unstructured":"Pokrzywinski R, Hareendran A, Nalysnyk L, et al. Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective. Sci Rep. 2021;11(1):20972.","journal-title":"Sci Rep"},{"issue":"2","key":"3481_CR14","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1542\/peds.2007-3016","volume":"122","author":"MM McGovern","year":"2008","unstructured":"McGovern MM, Wasserstein MP, Giugliani R, et al. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics. 2008;122(2):e341\u20139.","journal-title":"Pediatrics"},{"issue":"1","key":"3481_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13023-021-01842-0","volume":"16","author":"MM McGovern","year":"2021","unstructured":"McGovern MM, Wasserstein MP, Bembi B, et al. Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation. Orphanet J Rare Dis. 2021;16(1):212.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3481_CR16","first-page":"330","volume":"65","author":"ECB Eskes","year":"2024","unstructured":"Eskes ECB, van Dussen L, Aerts JMFG, et al. Acid sphingomyelinase deficiency and Gaucher disease in adults: similarities and differences in two macrophage storage disorders. JIMD Rep. 2024;65(5):330\u201340.","journal-title":"JIMD Rep"},{"issue":"1-2","key":"3481_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ymgme.2020.06.008","volume":"131","author":"SA Jones","year":"2020","unstructured":"Jones SA, McGovern M, Lidove O, et al. Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy. Mol Genet Metab. 2020;131(1\u20132):116\u201323.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3481_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s13023-022-02587-0","volume":"17","author":"GA Diaz","year":"2022","unstructured":"Diaz GA, Giugliani R, Guffon N, et al. Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results. Orphanet J Rare Dis. 2022;17(1):437.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3481_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10545-017-0123-6","volume":"41","author":"MP Wasserstein","year":"2018","unstructured":"Wasserstein MP, Diaz GA, Lachmann RH, et al. Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months. J Inherit Metab Dis. 2018;41(5):829\u201338.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3481_CR20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s13023-023-02983-0","volume":"18","author":"MP Wasserstein","year":"2023","unstructured":"Wasserstein MP, Lachmann R, Hollak C, et al. Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial. Orphanet J Rare Dis. 2023;18(1):378.","journal-title":"Orphanet J Rare Dis"},{"key":"3481_CR21","volume":"38","author":"R Pulikottil-Jacob","year":"2024","unstructured":"Pulikottil-Jacob R, Dehipawala S, Smith B, et al. Survival of patients with chronic acid sphingomyelinase deficiency (ASMD) in the United States: a retrospective chart review study. Mol Genet Metab Rep. 2024;38:101040.","journal-title":"Mol Genet Metab Rep"},{"key":"3481_CR22","unstructured":"Modi P, Goldin J, Cascella M. Diffusing capacity of the lungs for carbon monoxide. StatPearls. Treasure Island: StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC.; 2024."},{"issue":"12","key":"3481_CR23","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/ppul.20725","volume":"42","author":"N Guillemot","year":"2007","unstructured":"Guillemot N, Troadec C, de Villemeur TB, Cl\u00e9ment A, Fauroux B. Lung disease in Niemann-Pick disease. Pediatr Pulmonol. 2007;42(12):1207\u201314.","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"3481_CR24","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/gim.2013.4","volume":"15","author":"MM McGovern","year":"2013","unstructured":"McGovern MM, Lippa N, Bagiella E, Schuchman EH, Desnick RJ, Wasserstein MP. Morbidity and mortality in type B Niemann-Pick disease. Genet Med. 2013;15(8):618\u201323.","journal-title":"Genet Med"},{"issue":"2","key":"3481_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ymgme.2018.11.014","volume":"126","author":"M Wasserstein","year":"2019","unstructured":"Wasserstein M, Dionisi-Vici C, Giugliani R, et al. Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD). Mol Genet Metab. 2019;126(2):98\u2013105.","journal-title":"Mol Genet Metab"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03481-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03481-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03481-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:14:05Z","timestamp":1775726045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03481-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3481"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03481-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wim A. Wuyts received funds for advisory boards from Sanofi, Boehringer Ingelheim, Alentis, and Roche. Francesco Bonella received speaker and advisor honoraria, and travel cost refunds from Sanofi, Boehringer Ingelheim and Savara Pharma. Maurizio Scarpa received research funding and honoraria from Sanofi, Takeda, Chiesi, Ultragenyx, Amicus, Azafaros, BioMarin, and Orchard. Venediktos Kapetanakis and Pragya Shukla are employees of Evidera, a part of Thermo Fisher Scientific, which received fees from Sanofi for the conduct of statistical analyses. Maja Gasparic and Marie Fournier are employees of Sanofi and may hold stocks and\/or stock options in the company. Ruth Pulikottil-Jacob was an employee of Sanofi at the time of study conduct and may hold stocks and\/or stock options in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is a post hoc analysis on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}